Autotaxin stimulates urokinase-type plasminogen activator expression through phosphoinositide 3-kinase-Akt-necrosis factor kappa B signaling cascade in human melanoma cells

Melanoma Research

Volumn 16, Issue 5, 2006, Pages 445-452

  Lee, Jangsoon ^a   Duk Jung, In ^a   Gyo Park, Chang ^a   Han, Jeung Whan ^b   Young Lee, Hoi ^a  

^a Konyang University   (South Korea)

^b Sungkyunkwan University   (South Korea)

Author keywords

Akt; Autotaxin; Necrosis factor B; Urokinase type plasminogen activator

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AUTOTAXIN; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSOPHOSPHOLIPASE; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR; PROTEASOME; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B BETA; PYRROLIDINE DITHIOCARBAMATE; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; CANCER CELL; CANCER INVASION; CELL NUCLEUS; DNA BINDING; DOSE RESPONSE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; HUMANS; MELANOMA; MICROSCOPY, FLUORESCENCE; MULTIENZYME COMPLEXES; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHODIESTERASE I; PHOSPHORYLATION; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-AKT; PYROPHOSPHATASES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; URINARY PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 33749431430     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000232293.14408.a4     Document Type: Article

References (39)

1. Dunn SE, Torres JV, Oh JS, Cykert DM, Barrett JC. Up-regulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res 2001; 6:1367-1374.
2. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003; 22:205-222.
3. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44:139-266.
4. Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 1992; 373:611-622.
5. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4:923-928.
6. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992; 267:2524-2529.
7. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134:1563-1571.
8. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72:1-22.
9. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997; 18:415-417.
10. Costantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, et al. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996; 77:1079-1088.
11. Quax PH, van Muijen GN, Weening-Verhoeff EJ, Lund LR, Dano K, Ruiter DJ, et al. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 1991; 115:191-199.
12. Yonemura Y, Nojima N, Kaji M, Fujimura T, Itoh H, Ninomiya I, et al. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 1995; 76:941-953.
13. Nerlov C, Rorth P, Blasi F, Johnsen M. Essential AP-1 and PEA3 binding elements in the human urokinase enhancer display cell type-specific activity. Oncogene 1991; 6:1583-1592.
14. Liotta LA, Schiffmann E. Tumour motility factors. Cancer Surv 1988; 7:631-652.
15. Stefan C, Gijsbers R, Stalmans W, Bollen M. Differential regulation of the expression of nucleotide pyrophosphatases/phosphodiesterases in rat liver. Biochim Biophys Acta 1999; 1450:45-52.
16. Kehlen A, Geisler M, Olsen J, Sablotzki A, Langner J, Riemann D. IL-10 and TGF-beta differ in their regulation of aminopeptidase N/CD13 expression in monocytes. Int J Mol Med 2004; 13:877-882.
17. Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, et al. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 2002; 19:603-608.
18. Stassar MJ, Devitt G, Brosius M, Rinnab L, Prang J, Schradin T, et al. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer 2001; 85:1372-1382.
19. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002; 158:227-233.
20. Koh E, Clair T, Woodhouse EC, Schiffmann E, Liotta L, Stracke M. Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities. Cancer Res 2003; 63:2042-2045.
21. Lee HY, Bae GU, Jung ID, Lee JS, Kim YK, Noh SH, et al. Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells. FEBS Lett 2002; 515:137-140.
22. Jung ID, Lee J, Yun SY, Park CG, Choi WS, Lee HW, et al. Cdc42 and Rac1 are necessary for autotaxin-induced tumor cell motility in A2058 melanoma cells. FEBS Lett 2002; 532:351-356.
23. Todaro GJ, Fryling C, De Larco JE. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc Natl Acad Sci USA 1980; 77:5258-5262.
24. Liotta LA, Guirguis RA, Schiffmann E. Tumor autocrine motility factor. Prog Clin Biol Res 1986; 212:17-24.
25. Bang OS, Park EK, Yang SI, Lee SR, Franke TF, Kang SS. Overexpression of Akt inhibits NGF-induced growth arrest and neuronal differentiation of PC12 cells. J Cell Sci 2001; 114:81-88.
26. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 2003; 278:28593-28606.
27. Song J, Clair T, Noh JH, Eun JW, Ryu SY, Lee SN, et al. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate. Biochem Biophys Res Commun 2005; 337:967-975.
28. Chou CH, Wei LH, Kuo ML, Huang YJ, Lai KP, Chen CA, et al. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis 2005; 26:45-52.
29. Raj GV, Sekula JA, Guo R, Madden JF, Daaka Y. Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB. Prostate 2004; 1:105-113.
30. Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res 2006; 66:4549-4552.
31. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 1999; 5:3704-3710.
32. Li H, Ye X, Mahanivong C, Bian D, Chun J, Huang S. Signaling mechanisms responsible for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells. J Biol Chem 2005; 280:10564-10571.
33. Sliva D, Rizzo MT, English D. Phosphatidylinositol 3-kinase and NF-kappaB regulate motility of invasive MDA-MB-231 human breast cancer cells by the secretion of urokinase-type plasminogen activator. J Biol Chem 2002; 277:3150-3157.
34. Bektas M, Payne SG, Liu H, Goparaju S, Milstien S, Spiegel S. A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells. J Cell Biol 2005; 169:801-811.
35. Symowicz J, Adley BP, Woo MM, Auersperg N, Hudson LG, Stack MS. Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res 2005; 65:2234-2242.
36. Yart A, Chap H, Raynal P. Phosphoinositide 3-kinases in lysophosphatidic acid signaling: regulation and cross-talk with the Ras/mitogen-activated protein kinase pathway. Biochim Biophys Acta 2002; 1582:107-111.
37. Lee J, Jung ID, Chang WK, Park CG, Cho DY, Shin EY, et al. p85 beta-PIX is required for cell motility through phosphorylations of focal adhesion kinase and p38MAP kinase. Exp Cell Res 2005; 307:315-328.
38. Saatian B, Zhao Y, He D, Georas SN, Watkins T, Spannhake EW, et al. Transcriptional regulation of lysophosphatidic acid-induced interleukin-8 expression and secretion by p38MAPK and JNK in human bronchial epithelial cells. Biochem J 2006; 293:657-668.
39. Lee H, Lin CI, Liao JJ, Lee YW, Yang HY, Lee CY, et al. Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-kappaB-dependent mechanism. Am J Physiol Cell Physiol 2004; 287:C1657-C1666.